New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky is committed to reducing these numbers.
According to the National Cancer Institute, cancer is among the leading causes of death worldwide. And of those diagnosed in the United States, lung cancer accounts for 25 percent of cancer deaths. The numbers are sobering: one out of every two patients diagnosed with lung cancer won’t survive past 12 months.
In an effort to combat this problem, a collaboration between scientists from University of Kentucky College of Pharmacy, Memorial Sloan Kettering Cancer Center, and St. Jude Children’s Research Hospital brings researchers one step closer to a solution.
A compound developed by Dean Kip Guy’s lab of UK College of Pharmacy, with research that began at St. Jude Children’s Research Hospital, now provides us with a way to block cancer-causing proteins on a cellular level.
The groundwork began more than 10 years ago when Dr. Bhuvanesh Singh, a physician-scientist at Memorial Sloan Kettering Cancer Center, identified that an increase of a protein called DCN1 led to more malignant lung cancers and shorter life spans for his patients. Of the patients he studied, those with high levels of DCN1 succumbed to the disease more quickly than those with normal levels.
Frustrated by their findings, Singh’s team set out to study the specifics of DCN1. While DCN1 is a normally occurring protein, his team found that too much of it leads directly to cancer formation. Simply put, a malignant tumor was formed when the amount of DCN1 in a cell was increased. Thus, patients with more DCN1 got sick more quickly and died faster than their counterparts.
Efforts in Brenda Schulman’s lab at St. Jude, led by biochemist Daniel Scott, established how DCN1 interacts with other proteins and controls cellular processes. Their key discovery used X-ray crystallography to show that a small modification of the partner protein to DCN1, known as UBE2M was required for DCN1 to work. This modification, N-terminal acetylation (while common) had not previously been shown to be critical to controlling activity of this specific protein. Recognizing the potential for targeting this modification, Schulman reached out to form a collaboration between the three laboratories.
Their goal: to develop a way to stop DCN1 from killing patients.
Understanding the behavior and function of DCN1 was far more ambitious than running simple tests. It was a significant step forward in understanding how proteins within a cell work.
Building upon the science from Schulman’s team, Jared Hammill from Guy’s lab and Danny Scott from Schulman’s lab worked to stop the interactions of DCN1 all together. If DCN1’s activity depended on this interaction, then it stood to reason they could create a compound to intervene and stop the interaction from happening.
Guy describes the interaction as a “lock and key model.” Scientists have a blank key—which is UBE2M—and a lock, which is DCN1. The key wants to fit into the lock so it’s modified until it fits. This modification process is N-terminal acetylation.
“What’s the significance?” Guy said. “Well, we’re the first people to show that protein interaction controlled by N-terminal acetylation can be blocked. We’re essentially jamming the lock with a compound so the key won’t fit.”
The items jamming that lock are a series of small molecules created in the lab. When the molecules were tested directly in cancer cells, they worked. They effectively blocked DCN1 from binding to UB2EM. After decades of collaborative research, there was finally a barrier between lock and key.
The impact of these findings for healthcare and lung cancer patients specifically could be profound.
“We are excited about the implications of this research, which offer us a meaningful solution for addressing diseases like cancer, neurodegenerative disorders, and infection,” Schulman said. “It’s exciting to collaborate with so many complementary groups of expertise and to watch how Dr. Scott and Dr. Hammill led the team. This research opens many new doors for us.”
The collaboration between these three labs could mean relief to many of those suffering from a variety of diseases.
“To have spent decades on this research and have such promising results is truly exhilarating,” Singh said. “At the end of the day, what matters most is improving health outcomes for our patients. This work represents a very important step towards developing a new approach to treat the most difficult of cancers and hopefully increase cure rates.”
The Latest on: Block cancer
- Cancer: The red drink that ‘kills’ cancer cells and reduces tumour growth by up to 61%on January 19, 2022 at 2:36 pm
THE BURDEN of cancer is growing at full tilt, exerting strain on populations and health bodies worldwide. Although countermeasures against the disease are improving, the absence of a cure means ...
- I Have Pancreatic Cancer, and I’ve Defied the Odds—Here’s What's Helped Meon January 19, 2022 at 6:01 am
This is what a journey into the world of off-label cancer treatment looks like. In September 2018, the pain in my ribs and back erupted almost overnight. I ignored it at first, sure that I had done ...
- I Have Pancreatic Cancer, and I’ve Defied the Odds—but This Alternative Treatment Seemed to Help Meon January 19, 2022 at 6:00 am
After being diagnosed with deadly pancreatic cancer, one woman added an off-label regimen to her official treatments, and has lived longer than most with her condition.
- Cryptocurrency Unites With Susan G. Komen to End Breast Canceron January 19, 2022 at 5:00 am
Susan G. Komen® will now accept donations in the form of cryptocurrency. Komen is currently accepting more than 70 cryptocurrencies.
- Kids Cancer Hospital Is in the Path of Putin’s New Attack Routeon January 19, 2022 at 4:56 am
But the recent bromance between President Vladimir Putin and his Belarusian counterpart has opened up the terrifying possibility of a new line of attack. The southern border of Belarus is less than a ...
- Researchers identify novel pathways responsible for liver canceron January 18, 2022 at 4:20 am
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is one of leading causes of cancer-related deaths globally, with more than 700,000 new cases and 600,000 estimated ...
- Scientists discover cytochrome P450 family member CYP39A1 can block hepatocarcinogenesison January 17, 2022 at 1:20 pm
Hepatocellular carcinoma (HCC) is two to five times more common in men than in women. An in-depth analysis of the mechanisms underlying the gender heterogeneity of HCC may contribute to the ...
- Ganga Ram children’s block to get breast cancer uniton January 15, 2022 at 1:20 pm
LAHORE: Punjab Health Minister Dr Yasmin Rashid said on Saturday that the breast cancer treatment unit is part of the Ganga Ram Mother and Child block. The health minister called ...
- Guest opinion: Let’s eradicate cervical cancer once and for allon January 15, 2022 at 8:00 am
I continue to be hopeful about where we are headed. I invite you to join me as we spread the word about cervical cancer awareness and prevention during January, which is Cervical Cancer Awareness ...
- Moffitt Researchers Discover Regulatory Pathway That Blocks Immune Response Against Canceron January 9, 2022 at 2:09 pm
A hallmark of cancer is its ability to evade the immune system. It is why researchers are focused on finding new strategies and targets to jumpstart the immune system so it can mount a response ...
via Google News and Bing News